Thalidomide fails to boost mesothelioma outcomes
Adding maintenance thalidomide to standard first-line chemotherapy does not improve outcomes among patients with malignant pleural or peritoneal mesothelioma, study findings indicate.
Source: MedWire News - Respiratory - Category: Respiratory Medicine Source Type: news
More News: Asbestosis | Cancer & Oncology | Chemotherapy | Mesothelioma | Respiratory Medicine | Study